For instance, a targeted survey can measure the bottlenecks, including non-availability of stocks, equipment and staff, that healthcare facilities and their users face.
Several approaches have been used to improve the utility of such systems, depending on the source of the bottleneck, including mutagenesis of ncAA-RS active-site amino acids, optimization of the suppressor tRNA recognition, modification of RS proof-reading domains, replacement of endogenous tRNA/RS pairs, modification of elongation factors, and reassignment of chromosomal amber codons.
Alternative chromatography solutions to help remedy this bottleneck include the utilization of continuous processing systems such as periodic counter-current chromatography (PCC).
Major bottlenecks include the lack of robust staining, and adequate reconstruction and quantification techniques.
Critical bottlenecks include: (1) The Delphi panel, the selection and use of expertise [28, 12] (2) Formulation of the questions [e.g. 12, 29] (3) The use of other good methods [e.g. 12] (4) Interpretation of results (5) The factors which should be given special attention [e.g. 12] (6) Statistical interpretations of Delphi results [31]. .
Such consideration is based on a state-of-the-art analysis of the technology, indicating that technical and economical bottlenecks include pretreatment, saccharification and hexoses and pentoses fermentation.
However, current bottlenecks include a lack of infrastructure, standardisation, interoperability and anonymization of data within these biobanks.
The economics of subsequent DSP steps including cell disruption, extraction, and purification are not readily reported in literature but identified bottlenecks include overall sustainability related to energy costs and environmental impacts (Barsanti and Gualtieri 2018).
Notable bottlenecks include limited vector production capacity for γRV or LV vector stocks and difficulties in scaling production for larger trials.
Transferring established screening protocols from immortalized cell lines to primary cells is not trivial and technical bottlenecks include required cell numbers, susceptibility to small interfering RNA (siRNA) transfection, assay robustness and the issue of heterogeneity accompanying primary cells [ 17].
